 iBio Inc NYSE: IBIO has signed an exclusive license agreement with RubrYc Therapeutics Inc for RTX-003, an immunotherapy candidate targeting regulatory T cells Tregs. Related: IBio Adds Three Cancer Antibody Programs. 